Details
Zusammenfassung: <jats:title>Key Points</jats:title> <jats:p>Different point mutations in the PML moiety of PML-RARA mediate varying responses to arsenic treatment. Increasing the concentration of arsenic trioxide or combining it with ATRA may overcome the arsenic resistance driven by the acquired point mutations.</jats:p>
Umfang: 243-250
ISSN: 0006-4971
1528-0020
DOI: 10.1182/blood-2015-04-637678